ClinicalTrials.gov
public full text
Public Domain
Rh-Endostatin (Endostar®) Continuous Intravenous Infusion
Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous intravenous infusion by using venous pump can improve the compliance.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY#914228
- Data Collection, Clinical Care and Interventions in CCR, NCI#1088160
- Medical Council v Bukhari (Approved) [2026] IEHC 458 (22 June 2026)#366155
- ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis#968549
- Alefacept for Prevention of Graft Versus Host Disease (GVHD)#405158
Record · ID 890871
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive